EGFR mutations in lung cancer: from tissue testing to liquid biopsy. (June 2015)

• Record Type: Journal Article
• Authors: Fenizia, Francesca; De Luca, Antonella; Pasquale, Raffaella; Sacco, Alessandra; Forgione, Laura; Lambiase, Matilde; Iannaccone, Alessia; Chicchinelli, Nicoletta; Franco, Renato; Rossi, Antonio; Morabito, Alessandro; Rocco, Gaetano; Piccirillo, Maria Carmela; Normanno, Nicola
• Is Part Of: Future oncology. Volume 11:Number 11(2015)
• Page Start: 1611
• Page End: 1623
• Publication Date: 2015-06
• Subjects: EGFR mutations -- EGFR-TKIs -- liquid biopsy -- mechanisms of resistance -- non-small-cell lung carcinoma -- targeted therapy; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.23
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.